$MXCT News

MaxCyte® Announces Multi-Platform Technology License Partnership with Genentech® to Advance Cell Therapy Development

MaxCyte Enters Into Technology License Partnership With Genentech To Support Development Of Cell Therapy Programs

MaxCyte to Report Second Quarter 2026 Financial Results on August 12, 2026

VectorBuilder Partners With MaxCyte® to Advance Clinical-Grade Cell Engineering

Here’s Why MaxCyte (MXCT) is Becoming a High-Conviction Bet for Investors

MaxCyte Inc (MXCT) Q1 2026 Earnings Call Highlights: Revenue Meets Expectations Amid Core ...

MaxCyte, Inc. (MXCT) Q1 2026 Earnings Call Transcript

MaxCyte Q1 Earnings Call Highlights

MaxCyte, Inc. Q1 2026 Earnings Call Summary

MaxCyte, Inc. (MXCT) Reports Q1 Loss, Tops Revenue Estimates

MaxCyte (NASDAQ:MXCT) Q1 2026 Results Beat Estimates, Stock Rises on Buyback

MaxCyte Reports First Quarter 2026 Financial Results and Reiterates Full Year 2026 Guidance

MaxCyte Affirms FY2026 Sales Guidance of $30.000M-$32.000M vs $30.829M Est

MaxCyte Q1 EPS $(0.04) Beats $(0.07) Estimate, Sales $9.651M Beat $7.298M Estimate

MaxCyte to Report First Quarter 2026 Financial Results on May 12, 2026

MaxCyte Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

MaxCyte, Inc. Q4 2025 Earnings Call Summary

Craig-Hallum Maintains Buy on MaxCyte, Lowers Price Target to $5

MaxCyte Inc (MXCT) Q4 2025 Earnings Call Highlights: Navigating Revenue Declines Amid Strategic ...

MaxCyte, Inc. (MXCT) Q4 2025 Earnings Call Transcript